These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26335012)

  • 1. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
    Matsuda Y; Ishiwata T; Yoshimura H; Yamashita S; Ushijima T; Arai T
    Pancreas; 2016 Jan; 45(1):93-100. PubMed ID: 26335012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
    Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
    Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
    Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
    Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice.
    Matsuda Y; Yoshimura H; Ueda J; Naito Z; Korc M; Ishiwata T
    Am J Pathol; 2014 Mar; 184(3):674-85. PubMed ID: 24412093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.
    Song X; Chen H; Zhang C; Yu Y; Chen Z; Liang H; Van Buren G; McElhany AL; Fisher WE; Lonard DM; O'Malley BW; Wang J
    Cancer Lett; 2019 Feb; 442():310-319. PubMed ID: 30423406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
    Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo.
    Chen Y; Xie D; Yin Li W; Man Cheung C; Yao H; Chan CY; Chan CY; Xu FP; Liu YH; Sung JJ; Kung HF
    Cancer Lett; 2010 Nov; 297(1):109-16. PubMed ID: 20684863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
    Tan J; Zhou X; Zhu H
    Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer.
    Matsuda Y; Ishiwata T; Yoshimura H; Yamahatsu K; Minamoto T; Arai T
    Cancer Sci; 2017 Mar; 108(3):354-361. PubMed ID: 28002641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
    Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
    Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
    Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P
    Oncotarget; 2017 Feb; 8(6):9216-9229. PubMed ID: 27999205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
    Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
    Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.